• Today, TAKE’s portfolio of offerings covers a full range of services and solutions across the Life Sciences value chain. Right from Clinical development to regulatory affairs to pharma covigilance, your company offers clients the benefit of its domain expertise across Consulting, Services and Technology, enabling them to bring drugs to market safely, quickly and efficiently.
  • TAKE’s progress is bolstered by the growth of the Life Sciences R&D Outsourcing market, which will be worth USD 39 Billion by 2020. 75% of this opportunity is expected to be in Clinical Vertical, while Regulatory and Pharmacovigilance constitute 15% and 10% respectively of this market growth.
  • The year FY 18 has been exceptional in many ways. TAKE’s ability to ‘run differently’, foresee and direct its capabilities towards high-growth avenues has ensured its relevance, impact and positioning in the industry. TAKE registered a revenue of INR 1587 Cr (USD 246 Mn), an 18% growth over the previous year, bringing its CAGR for the last three years to a healthy 29.52%. Net Profits also grew by 9.4% over the previous year, at INR 160 Cr (USD 25 Mn) with a three-year CAGR of 31.9%.
  • The customer base for TAKE’s flagship IP for regulatory submissions, pharmaREADY, surpassed 150. TAKE enables almost 40% of the global regulatory submissions for a top global pharma company and 8% of the total regulatory submissions to USFDA (between 2013 and 2018) were through TAKE. TAKE conducted 7% of all Biosimilar trials in India in 2017. TAKE has expanded infrastructure across geographies – Chennai & Bangalore in India and Bogota in Columbia, South America – in the backdrop of customer demand and exciting market opportunities.
  • Your company will continue to scale up Clinical and Regulatory offerings by both organic and inorganic means. Towards this, the company enhanced its equity capital base by INR 250 Cr during the year, by way of a preferential allotment to its promoters.
  • During the year the Company disinvested its entire stake held (through TAKE Global Holdings Pte. Ltd., a direct subsidiary of the Company) in Towell TAKE Solutions LLC Muscat (Joint Venture with Towell) on March 28, 2018 for a consideration of USD 2,000,000. Further the step down subsidiaries under Towell TAKE Investments LLC, Muscat (Towell TAKE Solutions LLC, Muscat , TAKE Solutions MEA Limited, Dubai and Mirnah Technologies Systems Limited, Saudi Arabia) also got dis-invested in the process.
  • Regulators are working hard to speed up new drug approvals, with the USFDA approving a record 46 novel drugs in 2017, the highest in the last 21 years. The regulator has setup multiple paths for sponsors to bring their drugs to market faster, including Fast Track, Breakthrough Therapy, Priority Review and Accelerated Approval. Over 61% of the new drugs approved in 2017 came through at least one of these expedited pathways. Research shows that if a pharma company brings a blockbuster drug to market just one quarter earlier, they can add USD 1.4 Billion to their topline. TAKE’s patented Clinical Data Standardization process reduces the time taken for data standardization by 50% enabling companies to bring their drugs to market quickly!
  • Biosimilars are 30% less expensive, and hence, are gaining in popularity as austerity measures kick-in in Europe and the largely low- and middle-income populations in emerging markets look for affordable alternatives. TAKE conducted 7% of all Biosimilars studies in India in 2017 .
  • The oncology therapeutic area is set to grow at 12% CAGR between 2017 and 2024, fuelling the growth of the overall market. TAKE has supported over 650 oncology studies with some of the largest players in the therapeutic area.
  • In the Financial Year 2017-18, we have set records in winning deals of larger scope and duration than ever before. At the end of this year, the Life Sciences business accounted for 91%. In the Life Sciences vertical, revenues grew by 25.1% YoY to INR 13,982 Mn (a 30.16% growth in USD terms). This growth is a result of our focus on Life Sciences and our ability to build partnerships with our clients through transformational business models. Today, we are proud to be recognized as a preferred partner by several global marquee customers.
  • In this year, TAKE launched an ICH E6(R2) Readiness Assessment Framework to help industry players become pro actively compliant with the latest requirements to run successful clinical trials. To augment our breadth of knowledge and deepen our expertise, we initiated the institution of a Medical & Scientific Advisory Board. TAKE further leveraged its domain knowledge and technology expertise to launch OneClinical, an eClinical platform to the market. OneClinical delivers near real-time, high-quality data and optimizes clinical trials. Proven across a variety of global trials, the platform offers short setup time with low fixed costs, and provides global accessibility with near real-time data analytics and visualizations.
  • TAKE’s flagship IP for regulatory submissions, pharmaREADY, crossed a milestone 150 customers in this year. TAKE’s strong experience in regulatory affairs has enabled us to build a robust system for handling regulatory submissions world over. TAKE now makes regulatory submissions to authorities in over 130 countries, and has enabled almost 40% of global regulatory submissions for a top global pharma.
  • In the Financial Year 2017-18, the Supply Chain vertical has seen a decline in line with TAKE’s strategic aspiration to move towards a Life Sciences organization. In this year, we disinvested from Towell TAKE Investments LLC, Muscat. Revenues from Supply Chain stand at INR 1,890 Mn, a 16.7% decrease from FY 2017 revenues.
  • TAKE Solutions continues to derive majority of its revenues from USA. Revenues from USA grew by19.16%to Rs. 12,707 Mn in FY 2018 compared to Rs. 10,664 Mn in FY 2017 on account of new offerings in the Life Sciences vertical in the USA. Revenue from USA grew at a CAGR of 21.77% over the last 5 years.
  • Revenue from Europe grew moderately from Rs. 1,000 Mn in FY 2017 to Rs. 1,037 Mn during FY 2018 recording a growth of 3.75% over the last financial year. Europe contributed to 6.53% of total revenues in FY 2018. Revenue contribution from Asia-Pac stood at 13.41% in FY 2018 compared to 13.25% in FY 2017.

Leave a Reply

Your email address will not be published. Required fields are marked *